23 posts in this category, sorted most recent first.
BPC-157 is the most-asked-about peptide on the internet right now. Real animal data, almost no human data, a market full of vendors making big claims. Here's the honest version.
GHK-Cu is the rare peptide where the skin-care evidence is real, the hair claims are partial, and the injection protocols are mostly guesswork. Here's how to think about it.
Three drugs are about to change the GLP-1 conversation again. Orforglipron just got FDA approval. CagriSema is in phase 3 readouts. MariTide is the longer-tail bet. Here's the honest read on which deserves your patience and which is hype.
The scale tells you weight. DEXA tells you what you're actually losing. The patterns at 3, 6, and 12 months on tirzepatide are more nuanced than the trial averages suggest.
The most-quoted patient experience on tirzepatide is that the food noise stops. Here's what people mean by it, what's actually happening neurologically, and why it doesn't return for everyone after stopping.
Rapid weight loss is associated with bone density changes. The GLP-1 trial data on bone is more nuanced than the headlines suggest. Here's what's known, what's contested, and what to do about it.
Rapid weight loss can shift kidney function metrics in ways that look concerning but usually aren't. Here's what to track, what's normal, and when the labs mean something.
The mental health conversation around GLP-1s has gotten louder in the last year. Some of the signal is real and worth taking seriously. Some is noise. Here's the honest separation.
GLP-1s slow gastric emptying, which slows gallbladder contraction, which can produce stasis and stones. The counterintuitive prevention involves more fat, not less.
Rapid weight loss can trigger gout flares in patients prone to them. The mechanism is well-understood, the pattern is predictable, and the prevention is mostly straightforward.
Sleep changes on tirzepatide are real and patterned. Some are good (apnea improvement is well-documented), some are mixed (lighter sleep early on), some are bad if you ignore them. Here's the full picture.
Anesthesiologists are now routinely asking about GLP-1 use before procedures. The reason is real, the timing matters, and the conversation often happens too late if you don't bring it up first.
Tirzepatide is contraindicated in pregnancy, but the timing question is more nuanced than 'stop when you decide to try.' Here's the protocol most prescribers use, and why it usually doesn't get explained at the appointment.
Most prescribers don't order routine labs on tirzepatide unless something goes wrong. Here's the panel worth requesting at baseline, six months, and twelve months even when nothing has gone wrong.
The pancreatitis warning on GLP-1s has been around since the early days of the class. The accumulated evidence after 8 years of widespread use is more reassuring than the warning suggests, but the patient-level decision still has nuance.
Every tirzepatide prescription carries an FDA boxed warning about thyroid C-cell tumors. The data behind the warning is more specific than the warning itself, and it matters for who actually shouldn't take the drug.
The trial averages on regain mask substantial variance. The patterns that predict who keeps the loss and who doesn't are partly biological and partly behavioral.
The most common reader question I get from people who train regularly is whether tirzepatide will tank their lifts. The honest answer is more interesting than yes or no.
Microdosing GLP-1 went from a fringe biohacker idea to a question people ask their doctor. The clinical data is thinner than the discourse suggests, but it's not nothing. Here's what's known.
The semaglutide and tirzepatide effect on alcohol intake is real and well-documented. The mechanism is partly understood, the long-term safety data is thin, and the practical advice for users on the drug is more nuanced than 'one drink is fine.' What the 2026 SURMOUNT-OASIS and downstream trials add.
The credentialed clinicians have covered GLP-1 drugs for years. Here is what they actually say, not the clickbait version.
Heat degrades peptides. But not all peptides, not at all temperatures, not at all durations. The honest version of the cold-chain question.
The tirzepatide weight-loss trial that reset the market. Here is what it tested, what it found, and the parts the press skipped.